[go: up one dir, main page]

ZA200700779B - Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same - Google Patents

Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same

Info

Publication number
ZA200700779B
ZA200700779B ZA200700779A ZA200700779A ZA200700779B ZA 200700779 B ZA200700779 B ZA 200700779B ZA 200700779 A ZA200700779 A ZA 200700779A ZA 200700779 A ZA200700779 A ZA 200700779A ZA 200700779 B ZA200700779 B ZA 200700779B
Authority
ZA
South Africa
Prior art keywords
hepatitis
treatments
inhibitors
compositions
same
Prior art date
Application number
ZA200700779A
Other languages
English (en)
Inventor
Gonzalez Javier
Jewell Tanya Michelle
Li Hui
Linton Angelica
Tatlock John Howard
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ZA200700779B publication Critical patent/ZA200700779B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA200700779A 2004-08-18 2007-01-26 Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same ZA200700779B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60261804P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
ZA200700779B true ZA200700779B (en) 2008-11-26

Family

ID=35429645

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700779A ZA200700779B (en) 2004-08-18 2007-01-26 Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same

Country Status (43)

Country Link
US (3) US7151105B2 (xx)
EP (1) EP1781662B1 (xx)
JP (1) JP4372195B2 (xx)
KR (1) KR100851178B1 (xx)
CN (2) CN101006092B (xx)
AP (1) AP2313A (xx)
AR (1) AR050699A1 (xx)
AT (1) ATE506364T1 (xx)
AU (1) AU2005273619B2 (xx)
BR (1) BRPI0514425A (xx)
CA (1) CA2577525C (xx)
CR (2) CR8935A (xx)
CY (1) CY1111480T1 (xx)
DE (1) DE602005027580D1 (xx)
DK (1) DK1781662T3 (xx)
EA (1) EA012605B1 (xx)
EC (1) ECSP077264A (xx)
ES (1) ES2361845T3 (xx)
GE (2) GEP20115305B (xx)
GT (1) GT200500221A (xx)
HK (1) HK1109617A1 (xx)
HN (1) HN2005000449A (xx)
HR (1) HRP20110458T1 (xx)
IL (2) IL180933A (xx)
MA (1) MA28803B1 (xx)
MX (1) MX2007001527A (xx)
MY (1) MY146123A (xx)
NI (1) NI200700043A (xx)
NL (1) NL1029755C2 (xx)
NO (1) NO20071274L (xx)
NZ (1) NZ552874A (xx)
PE (1) PE20060677A1 (xx)
PL (1) PL1781662T3 (xx)
PT (1) PT1781662E (xx)
RS (1) RS51794B (xx)
SI (1) SI1781662T1 (xx)
SV (1) SV2007002202A (xx)
TN (1) TNSN07066A1 (xx)
TW (1) TWI376379B (xx)
UA (1) UA88909C2 (xx)
UY (1) UY29068A1 (xx)
WO (1) WO2006018725A1 (xx)
ZA (1) ZA200700779B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1781662T3 (pl) * 2004-08-18 2011-08-31 Pfizer Inhibitory zależnej od RNA polimerazy RNA wirusa zapalenia wątroby typu C, i kompozycje i terapie wykorzystujące je
BRPI0615016A2 (pt) 2005-08-24 2011-05-03 Pfizer compostos inibidores de hcv polimerase, métodos para prepará-los e forma cristalina
WO2008137126A2 (en) 2007-05-04 2008-11-13 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of hcv infection
EP2008996A1 (en) * 2007-06-27 2008-12-31 Syngeta Participations AG Process for the production of pyrazoles
JP5820722B2 (ja) 2008-06-06 2015-11-24 スシネキス インク シクロスポリン類似体及びｈｃｖ感染の治療におけるその使用
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
CN102203095A (zh) 2008-08-11 2011-09-28 葛兰素史密丝克莱恩有限责任公司 用于治疗变应性疾病、炎性疾病和感染性疾病的嘌呤衍生物
KR101616396B1 (ko) 2008-08-11 2016-04-28 글락소스미스클라인 엘엘씨 신규의 아데닌 유도체
UY32940A (es) 2009-10-27 2011-05-31 Bayer Cropscience Ag Amidas sustituidas con halogenoalquilo como insecticidas y acaricidas
MX2012004971A (es) 2009-10-30 2012-06-12 Boehringer Ingelheim Int Regimenes de dosificacion para terapia combinada del vhc, que comprende b1201335, interferon alfa y ribavirina.
EP2325173A1 (de) 2009-11-19 2011-05-25 Bayer CropScience AG Verfahren zum Herstellen von 5-Fluor-1-alkyl-3-fluoralkyl-1H-pyrazol-4-carbonsäurechloriden
CN102753173A (zh) * 2009-12-18 2012-10-24 贝林格尔.英格海姆国际有限公司 Hcv组合疗法
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
US8703754B2 (en) 2010-02-10 2014-04-22 Glaxosmithkline Llc 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate
ES2528646T3 (es) * 2010-05-20 2015-02-11 Bayer Intellectual Property Gmbh Procedimiento para la fabricación de 1-alquil-3-difluorometil-5-hidroxipirazoles
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
FR2972452B1 (fr) 2011-03-09 2013-03-15 Rhodia Operations Procede de preparation du difluoroacetonitrile et de ses derives
DK2850066T3 (en) 2012-05-14 2016-04-25 Bayer Cropscience Ag PROCESS FOR THE PREPARATION OF 1-alkyl-3-fluoroalkyl-1H-pyrazole-4-carboxylic acid chlorides
US9163027B2 (en) 2012-11-21 2015-10-20 Stategics, Inc. Substituted triazolo-pyrimidine compounds for modulating cell proliferation differentiation and survival
KR102261967B1 (ko) 2013-01-17 2021-06-07 바이엘 크롭사이언스 악티엔게젤샤프트 5-플루오로-1-메틸-3-디플루오로메틸-1h-피라졸-4-카브알데히드 제조 방법
NO2953942T3 (xx) 2013-02-06 2018-03-24
RU2016131792A (ru) 2014-01-03 2018-02-06 Байер Энимэл Хельс ГмбХ Новые пиразолил-гетероариламиды в качестве средств для борьбы с вредителями
ES2657424T3 (es) 2014-01-24 2018-03-05 Bayer Cropscience Aktiengesellschaft Procedimiento de preparación de 1-alquil-3-difluorometil-5-fluor-1H-pirazol-4-carbaldehídos y 1-alquil-3-difluorometil-5-fluor-1H-pirazol-4-carboxilatos
RU2676684C2 (ru) 2014-02-20 2019-01-10 ГлаксоСмитКлайн Интеллекчуал Проперти (No.2) Лимитед ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
TWI675827B (zh) 2014-06-03 2019-11-01 瑞士商愛杜西亞製藥有限公司 吡唑化合物
CA2967248A1 (en) 2014-11-13 2016-05-19 Glaxosmithkline Biologicals Sa Adenine derivatives which are useful in the treatment of allergic diseases or other inflammatory conditions
WO2017093180A1 (de) 2015-12-01 2017-06-08 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
CR20180286A (es) 2015-12-03 2018-07-16 Glaxosmithkline Ip Dev Ltd Dinucleotidos de purina cíclicos como moduladores de sting
NZ745957A (en) 2016-04-07 2020-07-31 Glaxosmithkline Ip Dev Ltd Heterocyclic amides useful as protein modulators
KR20180132783A (ko) 2016-04-07 2018-12-12 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 단백질 조절제로서 유용한 헤테로사이클릭 아미드
WO2018033455A1 (de) 2016-08-15 2018-02-22 Bayer Cropscience Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
IL267306B (en) 2016-12-16 2022-07-01 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
CA3050348A1 (en) 2017-02-06 2018-08-09 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
KR102622644B1 (ko) 2017-10-04 2024-01-10 바이엘 악티엔게젤샤프트 해충 방제제로서의 헤테로시클릭 화합물의 유도체
US20210238172A1 (en) 2017-10-05 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators and methods of using the same
US11377440B2 (en) 2017-10-05 2022-07-05 Glaxosmithkline Intellectual Property Development Limited Modulators of stimulator of interferon genes (STING)
CN111836815A (zh) 2018-03-12 2020-10-27 拜耳公司 作为害虫防治剂的稠合双环杂环衍生物
US20210169080A1 (en) 2018-04-20 2021-06-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
WO2020232378A1 (en) 2019-05-16 2020-11-19 Silicon Swat, Inc. Benzo[b][1,8]naphthyridine acetic acid derivatives and methods of use
EP3969438A1 (en) 2019-05-16 2022-03-23 Stingthera, Inc. Oxoacridinyl acetic acid derivatives and methods of use
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
CA3164751A1 (en) 2019-12-18 2021-06-24 Benjamin Joseph MORROW Compounds
CN112194620B (zh) * 2020-12-04 2021-02-26 苏州开元民生科技股份有限公司 一种2-乙基-4-氰基吡啶的制备方法
CN113563167B (zh) * 2021-07-16 2023-09-08 南通华祥医药科技有限公司 一种2-甲基-1-四氢萘酮的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3786063A (en) * 1971-05-24 1974-01-15 Universal Oil Prod Co Thiazolethiosulfonates
DE2155360C3 (de) * 1971-11-08 1980-04-03 Cassella Ag, 6000 Frankfurt Verfahren zur Herstellung von Acylbernsteinsäuredialkylestern
CA1140049A (en) * 1977-12-22 1983-01-25 Dke J.E. Helgstran Pharmaceutical preparations from derivatives of hydroxycarbonylphosphonic acid
US4326058A (en) * 1979-02-05 1982-04-20 Sumitomo Chemical Company, Limited Organo-phosphoric esters and their production and use
US4489077A (en) * 1983-03-23 1984-12-18 Warner-Lambert Company 3-Isoxa-zolyl-2H-1,2-benzothiazine-3-carboxamide, 1,1-dioxides
US6174868B1 (en) * 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
AU688344B2 (en) * 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
HUT75225A (en) 1993-11-19 1997-04-28 Parke Davis & Co 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5504104A (en) * 1993-11-19 1996-04-02 Warner-Lambert Company Tricyclic pyrone derivatives as protease inhibitors and antiviral agents
US5789440A (en) * 1993-11-19 1998-08-04 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5808062A (en) * 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
SI1142887T1 (en) 1993-11-19 2004-08-31 Parke, Davis & Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
US5834506A (en) * 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
NZ510013A (en) * 1998-09-11 2003-11-28 Warner Lambert Co Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors
US6512006B1 (en) * 1999-12-09 2003-01-28 Warner-Lambert Company HIV protease inhibitors
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) * 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
PL1781662T3 (pl) * 2004-08-18 2011-08-31 Pfizer Inhibitory zależnej od RNA polimerazy RNA wirusa zapalenia wątroby typu C, i kompozycje i terapie wykorzystujące je

Also Published As

Publication number Publication date
AP2007003918A0 (en) 2007-02-28
US7622605B2 (en) 2009-11-24
JP4372195B2 (ja) 2009-11-25
EP1781662A1 (en) 2007-05-09
MA28803B1 (fr) 2007-08-01
KR100851178B1 (ko) 2008-08-08
SI1781662T1 (sl) 2011-07-29
US20060122399A1 (en) 2006-06-08
BRPI0514425A (pt) 2008-06-10
EP1781662B1 (en) 2011-04-20
AP2313A (en) 2011-10-31
DE602005027580D1 (de) 2011-06-01
PT1781662E (pt) 2011-07-01
HRP20110458T1 (hr) 2011-07-31
NZ552874A (en) 2010-04-30
GT200500221A (es) 2006-06-21
EA200700338A1 (ru) 2007-08-31
US7151105B2 (en) 2006-12-19
HK1109617A1 (en) 2008-06-13
SV2007002202A (es) 2007-03-20
EA012605B1 (ru) 2009-10-30
TNSN07066A1 (fr) 2008-06-02
IL180933A0 (en) 2007-07-04
UA88909C2 (ru) 2009-12-10
PE20060677A1 (es) 2006-08-11
CY1111480T1 (el) 2015-08-05
NI200700043A (es) 2008-01-02
AU2005273619A1 (en) 2006-02-23
CN101538268B (zh) 2011-07-27
MY146123A (en) 2012-06-29
US20090281122A1 (en) 2009-11-12
UY29068A1 (es) 2006-03-31
TWI376379B (en) 2012-11-11
JP2008509984A (ja) 2008-04-03
CN101006092A (zh) 2007-07-25
ATE506364T1 (de) 2011-05-15
WO2006018725A1 (en) 2006-02-23
CN101006092B (zh) 2013-04-17
IL192919A0 (en) 2009-02-11
GEP20094751B (en) 2009-08-10
CA2577525A1 (en) 2006-02-23
GEP20115305B (en) 2011-10-10
CR8935A (es) 2007-07-24
CN101538268A (zh) 2009-09-23
ECSP077264A (es) 2007-04-26
RS51794B (en) 2011-12-31
DK1781662T3 (da) 2011-06-27
KR20070044057A (ko) 2007-04-26
NL1029755C2 (nl) 2006-10-18
TW200612898A (en) 2006-05-01
CA2577525C (en) 2010-03-30
ES2361845T3 (es) 2011-06-22
NO20071274L (no) 2007-05-14
MX2007001527A (es) 2007-03-27
US20070015764A1 (en) 2007-01-18
CR20110153A (es) 2011-04-26
PL1781662T3 (pl) 2011-08-31
AR050699A1 (es) 2006-11-15
HN2005000449A (es) 2009-10-30
IL180933A (en) 2011-08-31
AU2005273619B2 (en) 2009-05-28
US8268835B2 (en) 2012-09-18
NL1029755A1 (nl) 2006-02-21

Similar Documents

Publication Publication Date Title
ZA200700779B (en) Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase and compositions and treatments using the same
AU2003224371A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same
WO2007140200A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007140254A3 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A3 (en) Hcv ns5b inhibitors
NL1025544A1 (nl) Remmers van rna-afhankelijk rna-polymerase van hepatitis-c-virus en preparaten en behandelingen waarbij ze worden gebruikt.
IL219150A0 (en) Viral polymerase inhibitors and pharmaceutical compositions comprising thereof
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
WO2004073599A3 (en) Inhibitors of hepatitis c virus, compositions and treatments using the same
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
IL177503A0 (en) Inhibitors of hepatitis c virus ns3 protease
AU2003256619A8 (en) Thionucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
HUP0400726A3 (en) Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
EP1766094A4 (en) INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
AP2585A (en) Macrocyclic inhibitors of hepatitis C virus
AP2473A (en) Macrocyclic inhibitors of hepatitis C virus
EP1758453A4 (en) NUCLEOSIDE ANALOGUES OF C-PURINE AS RNA-DEPENDENT VIRAL RNA-POLYMERASE INHIBITORS
IL182583A0 (en) 4-methoxymethyl-pyrrolidine-2-carboxylic acid compounds and derivatives thereof as hepatitis c virus inhibitors
HK1116503A1 (en) Macrocyclic inhibitors of hepatitis c virus
EP2083825A4 (en) HEPATITIS C TREATMENT COMPOSITIONS AND METHODS OF USING HEPATITIS C TREATMENT COMPOSITIONS
EP1450809A4 (en) NUCLEOSIDES, THEIR PREPARATION AND USE AS AN INHIBITORS OF RNA VIRUS POLYMERASES
HUE026600T2 (hu) Készítmények és eljárások virális hepatitis kezelésére
HK1134676A1 (en) Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same c
EP1711516A4 (en) RNA POLYMERASE DEPENDENT OF HCV RNA